You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 25, 2024

Litigation Details for Shipp v. Gomez (N.D. Ill. 2022)


✉ Email this page to a colleague

« Back to Dashboard


Details for Shipp v. Gomez (N.D. Ill. 2022)

Date Filed Document No. Description Snippet Link To Document
2022-02-16 1 complaint Protector Shroud 2. 8,231,876 Wan Purified… AbbVie’s patents at the Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark… AbbVie patents (AbbVie removed one of the patents from its prior list) and that those patent claims … U.S. Patent No. 8,420,081 63. U.S. Patent No. 8,420,081 (the “’081 patent”), titled “… U.S. Patent No. 8,926,975 68. U.S. Patent No. 8,926,975 (the “’975 patent”), titled “ External link to document
2021-11-18 101 other proceeding involving the ’619 patent’s parent, U.S. Patent No. 8,420,081, lends further support to “water…indefinite, with terms in the ’792 patent being the most egregious. That patent, which AbbVie asserts covers…’s so-called “bufferless” patents, one of which, in violation of the Patent Dance confidentiality provisions… ARGUMENT The ’792 Patent The ’792 patent relates to methods for purifying … The ’619 and ’030 Patents The ’619 and ’030 patents share a common specification2 External link to document
2021-09-14 60 answer to complaint Protector Shroud 2. 8,231,876 Wan Purified…the ’081 patent, the ’975 patent, the ’973 patent, and the ’619 patent or any related patent because …the ’081 patent, the ’975 patent, the ’973 patent, and the ’619 patent due to Plaintiffs’ patent misuse…enforceable claim of the ’081 patent, the ’975 patent, the ’973 patent, and the ’619 patent, either literally or… claim of the ’081 patent, the ’975 patent, the ’973 patent, and the ’619 patent is invalid for failing External link to document
2021-09-20 63 order U.S. Patent No. 8,420,081 as one of the Ten Patents; and (3) the patent issuing from U.S. Patent Application…02889 to add (1) U.S. Patent No. 11,083,792; (2) the patent issuing from U.S. Patent Application No. 17/… related to the ten patents that will be subject to a first trial (“Ten Patents”)1, IT IS HEREBY ORDERED…9,187,559, 9,512,216, 11,083,792, and the patent issuing from U.S. Patent Application No. 17/137,201. Case…seek a preliminary injunction on any patents other than the Ten Patents. Plaintiffs shall not seek a preliminary External link to document
2021-11-14 99 stipulation Requests for Production related to U.S. Patent Nos. 6,805,686; 8,999,337; 9,067,992; 9,187,559; 9,512,216;…9,512,216; 11,083,792; and 11,167,030 (the patent issuing from U.S. Patent Application No. 17/137,201) (collectively…collectively, the “Remaining Patents”) by treating the term “Patents- in-Suit” as used in those Requests…served on August 25, 2021, to reflect all ten patents that will be tried in the August 2022 trial; and…Requests as including the Remaining Patents. AbbVie shall substantially complete this production on or before External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.